Management of Vaginal Candidiasis in Patients on SGLT-2 Inhibitors
Primary Recommendation
- The Centers for Disease Control and Prevention recommends treating vaginal candidiasis in patients on SGLT-2 inhibitors with standard topical azole therapy for 7 days, and most patients can continue their SGLT-2 inhibitor with appropriate antifungal treatment 1
Treatment Approach
First-Line Therapy
- The American College of Obstetricians and Gynecologists suggests using standard topical azole antifungals, such as Clotrimazole 1% cream 5g intravaginally for 7-14 days, Miconazole 2% cream 5g intravaginally for 7 days, or Terconazole 0.4% cream 5g intravaginally for 7 days 1
- Topical formulations achieve 80-90% cure rates with symptom relief and negative cultures after therapy completion, according to the Centers for Disease Control and Prevention 2, 1
Management of Complicated or Recurrent Cases
- For severe vulvovaginitis, the Centers for Disease Control and Prevention recommends extending topical azole therapy to 7-14 days or using Fluconazole 150mg in two sequential doses (second dose 72 hours after initial dose) 3
- For recurrent vulvovaginal candidiasis, the Centers for Disease Control and Prevention suggests obtaining vaginal cultures to confirm diagnosis and identify non-albicans species, using longer initial therapy, and considering maintenance therapy with fluconazole 100-150mg once weekly for 6 months 3
- For non-albicans species, the Centers for Disease Control and Prevention recommends extending therapy to 7-14 days with non-fluconazole azole or using boric acid 600mg vaginal capsule once daily for 2 weeks 3
Diagnostic Confirmation
- The Centers for Disease Control and Prevention recommends confirming diagnosis with clinical symptoms, vaginal pH ≤4.5, wet preparation or Gram stain showing yeasts or pseudohyphae, or positive culture 2